AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the of Autolus’ website.

Contact:

Olivia Manser

+44 (0) 7780 471568

Julia Wilson

+44 (0) 7818 430877 

Susan A. Noonan

S.A. Noonan Communications

 



EN
23/04/2024

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Abstract for longer-term follow-up and additional data analysis of Piv...

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was ...

April 24, 2024 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Report First Quarter 2024 Financial Results an...

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general bu...

April 23, 2024 1 EN
Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Thomas Vranken
AUTL Autolus Therape...

Autolus FIRST LOOK: European dossier acceptance for obe-cel

The EMA has accepted the marketing authorisation application for review of obe-cel for r/r B-ALL, following the earlier acceptance by the FDA in January 2024. Looking ahead, Autolus is set for an eventful year with the FDA decision on obe-cel (PDUFA 16 November), as well as multiple data readouts including initial data from the phase 1 SLE trial by YE24, which we think could position obe-cel to become a pipeline in a product. We reiterate our BUY rating and $11 TP.

AUTL AUTOLUS THERAPEUTICS ADS
04/02/24 April 2, 2024 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics announces acceptance of Marketing Authorization A...

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action date of November 16, 2024 LONDON, April 02, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceu...

April 2, 2024 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics Announces Changes to its Board of Directors LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director. John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director. These changes are effective as of today, April 1, 2024. “On behalf of the Board and Managemen...

April 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch